New “Buy” Rating Was Given to Vanda Pharmaceuticals (NASDAQ:VNDA)

September 15, 2018 - By Robert Sims

Investors sentiment increased to 1.53 in 2018 Q2. Its up 0.57, from 0.96 in 2018Q1. It improved, as 10 investors sold Vanda Pharmaceuticals Inc. shares while 33 reduced holdings. 18 funds opened positions while 48 raised stakes. 47.64 million shares or 3.78% more from 45.90 million shares in 2018Q1 were reported.

North Star Inv Management, a Illinois-based fund reported 5,000 shares. Geode Capital Ltd Liability Corporation accumulated 564,920 shares. Neuberger Berman Gru Ltd Limited Liability Company reported 30,000 shares. Proshare Advisors Ltd Limited Liability Company accumulated 0% or 28,661 shares. 131,265 are held by Wells Fargo And Mn. Northern Trust has 678,954 shares. Deutsche Bancshares Ag invested in 109,409 shares or 0% of the stock. Clarivest Asset Management Ltd Co reported 40,678 shares. J Goldman And Lp accumulated 140,647 shares. California State Teachers Retirement accumulated 78,585 shares. Daiwa Securities Group Incorporated has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 248 shares. Financial Architects Inc owns 5,000 shares. Virginia Retirement Et Al reported 39,600 shares. Piedmont Limited Co invested in 892 shares. Acadian Asset Mngmt Lc has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Why Has Stifel Nicolaus Given Vanda Pharmaceuticals (NASDAQ:VNDA) a $30 Price Target

Stifel Nicolaus has just issued a “Buy” rating for Vanda Pharmaceuticals (NASDAQ:VNDA) shares. The firm initiated coverage on shares of VNDA in a research note revealed to investors and clients on Friday, 14 September. This PT gives upside of 50.75 % from the previous close of Vanda Pharmaceuticals (NASDAQ:VNDA).

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 2 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Vanda Pharmaceuticals had 2 analyst reports since May 23, 2018 according to SRatingsIntel.

The stock increased 7.57% or $1.4 during the last trading session, reaching $19.9. About 1.06 million shares traded or 110.46% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 6.96% since September 15, 2017 and is uptrending. It has underperformed by 8.66% the S&P500.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on November, 6. They expect $-0.01 EPS, up 90.00 % or $0.09 from last year’s $-0.1 per share. After $0.09 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -111.11 % negative EPS growth.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.04 billion. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 737.04 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More news for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were recently published by: Seekingalpha.com, which released: “HETLIOZ driving study demonstrates no impairment in next morning performance” on September 13, 2018. Seekingalpha.com‘s article titled: “Premarket analyst action – healthcare” and published on August 23, 2018 is yet another important article.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.